MedTrace Logo

Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy

NCT00233402 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 789

Last updated 2013-10-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to document the additional detection of papillary bladder cancer and the reduced early recurrence due to the improved detection and resection of these tumors after Hexvix cystoscopy compared to standard cystoscopy in patients with papillary bladder cancer.

Conditions

Interventions

DRUG

Hexvix

Single Instillation, Transurethral Resection of the Bladder

PROCEDURE

Standard white light cystoscopy

Sponsors & Collaborators

  • Photocure

    lead INDUSTRY

Principal Investigators

  • H Barton Grossman · The University of Texas, MD Anderson Cancer Center, Department of Urology

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2008-07-31
Completion
2008-08-31

Countries

  • United States
  • Austria
  • Canada
  • Germany
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00233402 on ClinicalTrials.gov